Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
Smadja D.M. Ivak P. Pya Y. Latremouille C. Gustafsson F. Roussel J.C. Vincentelli A. Flecher E. Jansen P. Netuka I.
September 2022Elsevier Inc.
Journal of Heart and Lung Transplantation
2022#41Issue 91214 - 1217 pp.
anticoagulation , low molecular weight heparin , total artificial heart
Text of the article Перейти на текст статьи
Hematology department and Biosurgical Research lab (Carpentier Foundation), Université de Paris, Innovative Therapies in Hemostasis, Georges Pompidou European Hospital, Paris, France
Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
National Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan
Carmat SA, Velizy-Villacoublay, France
Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
Cardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, Saint-Herblain, France
Department of Cardiac Surgery, Univ. Lille, CHU Lille, France
Division of Cardiothoracic and Vascular Surgery, Pontchaillou University Hospital, Rennes, France
Hematology department and Biosurgical Research lab (Carpentier Foundation)
Department of Cardiovascular Surgery
National Research Cardiac Surgery Center
Carmat SA
Department of Cardiology
Cardiac and thoracic Surgery Department
Department of Cardiac Surgery
Division of Cardiothoracic and Vascular Surgery
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026